Real-world experience of angiotensin receptor/neprilysin inhibitor (ARNI) usage in Thailand: a single-center, retrospective analysis

Real-world experience of angiotensin receptor/neprilysin inhibitor (ARNI) usage in Thailand: a single-center, retrospective analysis

Abstract Background Treatment of heart failure with reduced ejection fraction (HFrEF) has been revolutionized by angiotensin receptor/neprilysin inhibitor (ARNI). ARNI has been shown to significantly reduce morbidity and mortality in a large, randomized controlled trial. However, real-world evaluati...

Full description

Bibliographic Details
Main Authors: Wipharak Rattanavipanon, Thanyaluck Sotananusak, Fairus Yamaae, Arisa Chandrsawang, Pitchapa Kaewkan, Surakit Nathisuwan, Teerapat Yingchoncharoen
Format: Article
Language:English
Published: BMC 2021-07-01
Series:BMC Cardiovascular Disorders
Subjects:
Heart failure
Sacubitril
Valsartan
Angiotensin receptor
Neprilysin inhibitor
Online Access:https://doi.org/10.1186/s12872-021-02145-9

Internet

https://doi.org/10.1186/s12872-021-02145-9

Similar Items